Copyright
©The Author(s) 2015.
World J Gastroenterol. Jan 7, 2015; 21(1): 254-261
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.254
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.254
Table 1 Predictive factors for cyclosporine response
Responders (n = 19) | Non-responders(n = 10) | P value | |
Clinical factor | |||
Fever (°C) ≥ 38.5: < 38.5 | 10:9 | 6:4 | P = 1.000 NS |
Hb (g/dL) | 10.6 | 9.8 | P = 0.317 NS |
CAI score | 14.6 | 15.0 | P = 0.575 NS |
Age (yr) | 32.8 | 34.3 | P = 0.804 NS |
Duration (mo) | 67.7 | 57.9 | P = 0.703 NS |
CRP (mg/dL) | 6.5 | 3.6 | P = 0.104 NS |
Endoscopic finding | |||
Endoscopic index | 9.9 | 10 | P = 0.819 NS |
Deep or geographical ulcer | 89.5% (17:2) | 50% (5:5) | P = 0.111 NS |
Mucosal bleeding | 42.1% (8:11) | 100% (10:0) | P = 0.004 |
Poor extensibility | 31.6% (6:13) | 70% (7:3) | P = 0.064 NS |
Pus-like discharge | 89.5% (17:2) | 90% (9:1) | P = 1.000 NS |
Table 2 Demographic data and clinical features of responders
Total (n = 15) | |
Sex (patient number) | |
Male | 9 |
Female | 6 |
Age at onset (yr; mean ± SE) | 26.2 ± 3.5 |
Age at CyA treatment (yr; mean ± SE) | 30.5 ± 3.8 |
Duration of UC (months; mean ± SE) | 62.3 ± 19.2 |
Disease extent (patient number) | |
Pancolitis | 12 |
Left-sided colitis | 3 |
Clinical course (patient number) | |
Relapse-remitting | 11 |
Chronic continuous | 3 |
Acute fulminating | 1 |
Initial attack | 0 |
Table 3 Clinical data and outcome of responders to CyA therapy
Endoscopic findings1 | Clinical factors1 | ||||||||||
Case No. | Age | Sex | Duration of UC | Disease extent | Poor extensibility | Deep ulcer | Mucosal bleeding | CAI | CRP | Hgb | Outcome |
1 | 23 | F | 24M | Pancolitis | (-) | (+) | (-) | 17 | 3.2 | 9.3 | Operation at 4M |
2 | 37 | M | 67M | Pancolitis | (-) | (+) | (+) | 16 | 1.5 | 10.9 | No operation |
3 | 23 | M | 44M | Pancolitis | (-) | (+) | (-) | 15 | 7.0 | 13.7 | Operation at 1Y, 4M |
4 | 32 | F | 77M | Pancolitis | (-) | (-) | (-) | 14 | 1.3 | 8.6 | Operation at 2Y, 10M |
5 | 31 | F | 26M | Pancolitis | (-) | (-) | (-) | 13 | 12.8 | 13.4 | No operation |
6 | 9 | F | 13M | Pancolitis | (-) | (-) | (-) | 15 | 12.5 | 13.2 | Operation at 5M |
7 | 16 | M | 79M | Lt-sided colitis | (-) | (+) | (-) | 15 | 12.8 | 11.9 | Operation at 1M |
8 | 16 | F | 1M | Pancolitis | (-) | (+) | (-) | 17 | 8.1 | 8.7 | No operation |
9 | 31 | M | 65M | Lt-sided colitis | (-) | (+) | (-) | 12 | 14.7 | 10.0 | No operation |
10 | 21 | M | 22M | Pancolitis | (-) | (+) | (-) | 17 | 6.4 | 11.8 | No operation |
11 | 49 | M | 27M | Lt-sided colitis | (+) | (+) | (+) | 13 | 13.7 | 7.8 | No operation |
12 | 29 | F | 47M | Pancolitis | (+) | (+) | (+) | 13 | 4.6 | 8.0 | No operation |
13 | 61 | M | 9M | Pancolitis | (+) | (+) | (-) | 15 | 0.4 | 10.7 | No operation |
14 | 54 | M | 300M | Pancolitis | (+) | (+) | (+) | 12 | 7.1 | 13.5 | No operation |
15 | 26 | M | 134M | Pancolitis | (+) | (+) | (+) | 18 | 4.1 | 10.9 | Operation at 2M |
Table 4 Following therapies for initial cyclosporine responders
Maintenance therapy | Total(n = 15) | Outcome | |
Colectomy (n = 6) | No colectomy (n = 9) | ||
Without azathioprine | |||
PSL | 1 | 1 | |
5-ASA+PSL | 4 | 3 | 1 |
PSL+neoral | 1 | 1 | |
5-AZA+PSL+neoral+LCAP | 1 | 1 | |
With azathioprine | |||
5-ASA+PSL+AZA | 1 | 1 | |
5-ASA+PSL+neoral+AZA | 5 | 5 | |
5-ASA+PSL+neoral+TAC+AZA | 1 | 1 | |
5-ASA+PSL+neoral+LCAP+AZA | 1 | 1 |
Table 5 Demographic data and clinical features of patients according to long-term prognosis
Colectomy (n = 6) | No colectomy (n = 9) | P value | |
Male:Female (patient no.) | 2:4 | 6:3 | P = 0.315 NS |
Age at onset (yr; mean ± SE) | 17.0 ± 2.8 | 32.3 ± 4.6 | P = 0.063 NS |
Age at CyA treatment (yr; mean ± SE) | 21.5 ± 3.3 | 36.6 ± 5.1 | P = 0.099 NS |
Duration of UC (mo; mean ± SE) | 61.8 ± 18.1 | 62.7 ± 30.6 | P = 0.982 NS |
CAI score pre-CyA (mean ± SE) | 15.7 ± 0.6 | 14.2 ± 0.7 | P = 0.164 NS |
CAI score post-CyA (mean ± SE) | 5.0 ± 1.0 | 5.6 ± 1.2 | P = 0.732 NS |
CRP pre-CyA (mean ± SE) | 6.8 ± 2.0 | 7.7 ± 1.7 | P = 0.726 NS |
Hb (mean ± SE) | 11.3 ± 0.8 | 10.5 ± 0.7 | P = 0.520 NS |
Disease extent (patient No.) | |||
Pancolitis: Lt-sided colitis | 5:1 | 7:2 | P = 1.000 NS |
Clinical course (patient No.) | P = 0.446 NS | ||
Relapse-remitting | 4 | 7 | |
Chronic continuous | 1 | 2 | |
Acute fulminating | 1 | 0 | |
Initial attack | 0 | 0 | |
Endoscopic findings | |||
Poor extensibility (+):(-) | 1:5 | 4:5 | P = 0.584 NS |
Deep ulcer (+):(-) | 4:2 | 8:1 | P = 0.523 NS |
Mucosal bleeding (+):(-) | 1:5 | 4:5 | P = 0.580 NS |
Table 6 Outcome according to each following therapy after cyclosporine
Colectomy (n = 6) | No colectomy (n = 9) | P value | |
Maintenance therapy | |||
PSL | 6 | 9 | |
LCAP | 1 | 0 | P = 0.4000 NS |
5-ASA | 4 | 9 | P = 0.1429 NS |
Neoral | 2 | 7 | P = 0.1357 NS |
AZA | 0 | 8 | P = 0.0014 |
- Citation: Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Maeda K, Morise K, Matsushita M, Furukawa K, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. World J Gastroenterol 2015; 21(1): 254-261
- URL: https://www.wjgnet.com/1007-9327/full/v21/i1/254.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i1.254